Li Guangyao, Javed Muhammad, Rasool Rubab, Abdel-Maksoud Mostafa A, Mubarak Ayman S, Studenik Christian R, Narayanan J, Atuahene Sampson Agyapong, Aufy Mohammed, Cao Kun
Department of Gastrointestinal Surgery, The Second People's Hospital of Wuhu Wuhu, Anhui, The People's Republic of China.
Primary and Secondary Health Care Department Lahore, Pakistan.
Am J Transl Res. 2023 Mar 15;15(3):1590-1606. eCollection 2023.
Cancer is one of the most prominent causes of death world wide. Identification of novel cancer biomarkers woud help with cancer diagnosis and possible treatment.
In this study, we comprehensively studied the diagnostic, prognostic, and therapeutic values of the hepatitis A virus cellular receptor 1 (HAVCR1) gene across multiple cancers from a pan-cancer point of view via a detailed approach.
HAVCR1 expression was up-regulated in a variety of malignancies. The up-regulated HAVCR1 was closely related to the poor prognosis in patients with esophageal carcinoma (ESCA), lung adenocarcinoma (LUAD), and stomach adenocarcinoma (STAD). Moreover, DAVID analysis showed that HAVCR1, along with different other associated genes, was involved in numerous cancer-associated signaling pathways across ESCA, STAD, and LUAD. Furthermore, in these cancers, HAVCR1 was also found closely associated with some other parameters such as promoter methylation, tumor purity, level of CD8+ T immune cells, genomic alterations, and chemotherapeutic drugs.
HAVCR1 was overexpressed in multiple tumors. However, the up-regulated HAVCR1 is a valuable diagnostic and prognostic biomarker as well as a therapeutic target in only ESCA, STAD, and LUAD patients.
癌症是全球最主要的死因之一。鉴定新型癌症生物标志物将有助于癌症诊断及可能的治疗。
在本研究中，我们通过详细的方法，从泛癌角度全面研究了甲型肝炎病毒细胞受体1（HAVCR1）基因在多种癌症中的诊断、预后和治疗价值。
HAVCR1表达在多种恶性肿瘤中上调。上调的HAVCR1与食管癌（ESCA）、肺腺癌（LUAD）和胃腺癌（STAD）患者的不良预后密切相关。此外，DAVID分析表明，HAVCR1与不同的其他相关基因一起，参与了ESCA、STAD和LUAD中众多与癌症相关的信号通路。此外，在这些癌症中，还发现HAVCR1与其他一些参数密切相关，如启动子甲基化、肿瘤纯度、CD8 + T免疫细胞水平、基因组改变和化疗药物。
HAVCR1在多种肿瘤中过表达。然而，上调的HAVCR1仅在ESCA、STAD和LUAD患者中是一种有价值的诊断和预后生物标志物以及治疗靶点。
